The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The chemosensitizing properties of iniparib in combination with gemcitabine (G) and carboplatin (C) in OVCAR-3 ovarian adenocarcinoma.
V. Ossovskaya
Employment or Leadership Position - BiPar Sciences
Consultant or Advisory Role - Sanofi
Stock Ownership - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Expert Testimony - Sanofi
Other Remuneration - Sanofi
C. Lim
No relevant relationships to disclose
G. Schools
No relevant relationships to disclose
S. Kalurupalle
No relevant relationships to disclose
E. Broude
No relevant relationships to disclose
I. B. Roninson
No relevant relationships to disclose